Patents by Inventor David H. Perlmutter

David H. Perlmutter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Transgenic comprising a human protein with a tendency to aggregate fused to a fluorescent protein
    Patent number: 9844605
    Abstract: The present invention relates to methods and compositions for high content drug screening in Caenorhabditis elegans which may be used to identify compounds that treat disorders associated with protein aggregation. It is based, at least in part, on the discovery that Caenorhabditis elegans, genetically modified to create a model system for disorders of protein aggregation, could be used, in a high throughput screening system, to identify agents that reduce the amount of aggregated protein.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: December 19, 2017
    Assignee: THE UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Stephen C. Pak, David H. Perlmutter, Gary A. Silverman
  • AUTOMATED HIGH-CONTENT LIVE ANIMAL DRUG SCREENING USING C. ELEGANS
    Publication number: 20140331341
    Abstract: The present invention relates to methods and compositions for high content drug screening in C. elegans which may be used to identify compounds that treat disorders associated with protein aggregation.
    Type: Application
    Filed: July 18, 2014
    Publication date: November 6, 2014
    Applicant: University of Pittsburgh - of the Commonwealth System of Higher EdUcation
    Inventors: Stephen C. Pak, David H. Perlmutter, Gary A. Silverman
  • Automated high-content live animal drug screening using
    Patent number: 8809617
    Abstract: The present invention relates to methods and compositions for high content drug screening in C. elegans which may be used to identify compounds that treat disorders associated with protein aggregation.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: August 19, 2014
    Assignee: The University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Stephen C. Pak, David H. Perlmutter, Gary A. Silverman
  • AUTOMATED HIGH-CONTENT LIVE ANIMAL DRUG SCREENING USING C. ELEGANS
    Publication number: 20110154510
    Abstract: The present invention relates to methods and compositions for high content drug screening in C. elegans which may be used to identify compounds that treat disorders associated with protein aggregation.
    Type: Application
    Filed: September 14, 2010
    Publication date: June 23, 2011
    Inventors: Stephen C. Pak, David H. Perlmutter, Gary A. Silverman
  • Methods to treat &agr;1-antitrypsin deficiency
    Patent number: 6656912
    Abstract: Inhibitors of glucosidase, especially those related to castanospermine, are effective in preventing or ameliorating conditions such as liver damage and emphysema that are present in individuals who produce a mutant form of antitrypsin, &agr;1-ATZ. Also effective in the method of the invention are imino sugars and their reduced forms in general as well as phenylbutyric acid. These compounds enhance the secretion of the mutant form, which retains substantial biological activity, and do not impair its degradation in the endoplasmic reticulum.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: December 2, 2003
    Assignee: Washington University in St. Louis
    Inventors: David H. Perlmutter, Nancy Marcus
  • Method for the treatment of alpha-1-antitrypsin deficiency and related pathologies
    Patent number: 6403646
    Abstract: A method for the treatment of alpha-1-antitrypsin deficiency caused by the protease inhibitor type Z mutation by administration of phenylbutyric acid derivatives. Also disclosed are methods for the prevention and treatment of liver injury and emphysema associated with alpha-1-antitrypsin deficiency by administration of phenylbutyric acid derivatives.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: June 11, 2002
    Inventors: David H. Perlmutter, Jon A. J. Burrows, Lauren K. Willis, Jeffery H. Teckman
  • Methods to treat alpha1-antitrypsin deficiency
    Publication number: 20020006909
    Abstract: Inhibitors of glucosidase, especially those related to castanospermine, are effective in preventing or ameliorating conditions such as liver damage and emphysema that are present in individuals who produce a mutant form of antitrypsin, &agr;1-ATZ. Also effective in the method of the invention are imino sugars and their reduced forms in general as well as phenylbutyric acid. These compounds enhance the secretion of the mutant form, which retains substantial biological activity, and do not impair its degradation in the endoplasmic reticulum.
    Type: Application
    Filed: January 22, 2001
    Publication date: January 17, 2002
    Inventors: David H. Perlmutter, Nancy Marcus
  • Method of blocking the SEC receptor
    Patent number: 5514653
    Abstract: A method is disclosed for blocking the SEC receptor and also inhibiting the neurotoxic effects of amyloid-.beta. protein by treating SEC receptor-bearing cells with a synthetic inhibitor peptide, e.g. peptide PB145.
    Type: Grant
    Filed: September 9, 1994
    Date of Patent: May 7, 1996
    Assignee: Washington University
    Inventor: David H. Perlmutter
  • Binding peptides
    Patent number: 5175253
    Abstract: Novel short peptides of up to about 20 amino acid residues are disclosed that bind to the SEC receptor. These novel peptides preferably are pentapeptides which are synthetic analogs of a pentapeptide domain in the carboxy-terminal fragment of .alpha..sub.1 -antitrypsin (amino acids 370-374, Phe-Val-Phe-Leu-Met [SEQ ID NO:2]). A preferred binding peptide is Phe-Val-Ala-Leu-Met [SEQ ID NO;6].
    Type: Grant
    Filed: April 24, 1991
    Date of Patent: December 29, 1992
    Assignee: Washington University
    Inventors: Robert J. Fallon, Joseph W. Bulock, Steven P. Adams, David H. Perlmutter